ProCE Banner Activity

First-line Hyper-CVAD Plus Ponatinib in Adults With Ph+ Acute Lymphoblastic Leukemia: Long-term Safety and Efficacy

Slideset Download
Conference Coverage
Assessment of first-line hyper-CVAD plus ponatinib in patients with Ph+ ALL demonstrates high response and survival rates and long-term tolerability with adjusted dosing.

Released: December 10, 2019

Expiration: December 08, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company